Eigenbrodt, Anna K.
Christensen, Rune Häckert
Ashina, Håkan
Iljazi, Afrim
Christensen, Casper Emil
Steiner, Timothy J.
Lipton, Richard B.
Ashina, Messoud
Article History
Received: 14 September 2022
Accepted: 17 October 2022
First Online: 12 November 2022
Declarations
:
: Not applicable.
: Not applicable.
: Håkan Ashina reports personal fees from Teva, outside of the submitted work.Casper Emil Christensen has received speaker fees from Teva pharmaceuticals and serves as a consultant for Teva pharmaceuticals.Timothy J Steiner is a Director and Trustee of <i>Lifting The Burden</i>.Richard B Lipton has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Dr. Reddy’s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff’s Headache</i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock/options in Biohaven, Ctrl M, and Manistee.Messoud Ashina is a consultant, speaker, or scientific advisor for AbbVie, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva and a primary investigator for ongoing AbbVie, Amgen and Lundbeck trials. He has no ownership interest and does not own stocks of any pharmaceutical company. He serves as associate editor of Cephalalgia, associate editor of the Journal of Headache and Pain, and associate editor of Brain.Anna K Eigenbrodt, Rune Häckert Christensen, and Afrim Iljazi, report no conflicts of interest.